Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Anixa Biosciences Inc Market Cap
From what 2 stock analysts predict, the share price for Anixa Biosciences Inc (ANIX) might increase by 157.58% in the next year. This is based on a 12-month average estimation for ANIX. Price targets go from $7 to $10. The majority of stock analysts believe ANIX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Anixa Biosciences Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Anixa Biosciences Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ANIX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason Kolbert D. Boral Capital | Buy | $10 | Maintains | Nov 19, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $7 | Reiterates | Nov 19, 2024 |
| Jason Kolbert D. Boral Capital | Buy | $10 | Maintains | Nov 11, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Sep 30, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Sep 24, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $7 | Reiterates | Sep 17, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Sep 9, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Initiates | Aug 7, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $7 | Reiterates | Jul 24, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $7 | Maintains | Jun 10, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Mar 21, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Feb 13, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Dec 7, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Sep 18, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 29, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Jul 28, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Jul 12, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Jun 19, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | May 23, 2023 |
| Matthew Barcus Chardan Capital | Buy | $9 | Reiterates | Apr 18, 2023 |
When did it IPO
1983
Staff Count
4
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Amit Kumar Ph.D.
Market Cap
$106.5M
In 2023, ANIX generated $210,000 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ANIX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 22 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Anixa Biosciences, Inc. (NASDAQ: ANIX) has approved the purchase of Bitcoin as a treasury reserve asset, enhancing its asset diversification strategy.
Why It Matters - Anixa's decision to buy Bitcoin as a treasury reserve signals a shift towards digital assets, potentially enhancing liquidity and attracting interest from crypto-focused investors.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Anixa Biosciences has dosed its first patient in the third cohort of a Phase 1 trial for its CAR-T therapy for recurrent ovarian cancer, using a dose ten times higher than the first cohort.
Why It Matters - The increase in CAR positive cell dosage signals a potential enhancement in treatment efficacy, which could lead to positive trial results, impacting Anixa's stock performance and investor confidence.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Anixa Biosciences presented positive Phase 1 trial data for its breast cancer vaccine, showing over 70% immune response in patients. A Phase 2 study is set to begin in 2025.
Why It Matters - Positive trial results and upcoming Phase 2 study for Anixa's breast cancer vaccine indicate strong potential for market approval and revenue growth, influencing investor confidence and stock performance.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Anixa Biosciences (NASDAQ: ANIX) will present additional data from its Phase 1 breast cancer vaccine trial on November 8, 2024, at the SITC Annual Meeting, available on its website.
Why It Matters - The upcoming data release on Anixa's breast cancer vaccine could significantly impact investor sentiment and stock price, reflecting progress in a high-stakes biotech sector.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Anixa Biosciences, Inc. (NASDAQ: ANIX) will present at the Sidoti Micro-Cap Virtual Conference on November 13-14, 2024, focusing on cancer treatment and prevention.
Why It Matters - Anixa's presentation at a micro-cap conference may attract investor interest, potentially influencing stock performance and increasing visibility for its cancer-focused innovations.
Mon, 28 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Anixa Biosciences (NASDAQ: ANIX) will present additional Phase 1 clinical trial data for its breast cancer vaccine at the SITC Annual Meeting from November 6-10, 2024.
Why It Matters - Positive data from Anixa's breast cancer vaccine trial could enhance investor confidence, potentially driving stock price up, especially ahead of a major industry conference.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
